Spots Global Cancer Trial Database for ensartinib
Every month we try and update this database with for ensartinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer | NCT05341583 | Non-small Cell ... | Ensartinib Placebo | 18 Years - | Betta Pharmaceuticals Co., Ltd. | |
| A Real World Study of Ensartinib in Advanced ALK-positive NSCLC | NCT05498064 | Carcinoma, Non-... Anaplastic Lymp... Ensartinib | Ensartinib | 18 Years - | Peking Union Medical College Hospital | |
| Expanded Access to Ensartinib for Participants With ALK+ NSCLC | NCT04146571 | Non-Small Cell ... ALK Gene Rearra... | Ensartinib | 18 Years - | Xcovery Holdings, Inc. | |
| Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer | NCT03737994 | Lung Non-Squamo... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... | Alectinib Brigatinib Carboplatin Ceritinib Cisplatin Crizotinib Ensartinib Lorlatinib Pemetrexed | 18 Years - | National Cancer Institute (NCI) | |
| A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung Cancer | NCT05380024 | Non Small Cell ... | Ensartinib | 18 Years - 75 Years | Peking University Cancer Hospital & Institute | |
| Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation | NCT05491811 | Non-Small Cell ... | Ensartinib Bevacizumab | 18 Years - | Sun Yat-sen University | |
| Ensatinib Treat Second-generation ALK-TKI Resistance After Second-generation ALK-TKI Resistance | NCT05178511 | The Diagnosis W... Second Generati... Efficacy of Ens... | Ensartinib | 18 Years - | Sun Yat-sen University | |
| Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer | NCT05341583 | Non-small Cell ... | Ensartinib Placebo | 18 Years - | Betta Pharmaceuticals Co., Ltd. | |
| Treating Patients With Melanoma and ALK Alterations With Ensartinib | NCT03420508 | Melanoma | Ensartinib ALKATI by Custo... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer | NCT05241028 | Non-small Cell ... | Ensartinib | 18 Years - 75 Years | Hebei Medical University Fourth Hospital | |
| Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) | NCT03155620 | Advanced Malign... Ann Arbor Stage... Ann Arbor Stage... Histiocytic Sar... Juvenile Xantho... Langerhans Cell... Malignant Gliom... Recurrent Child... Recurrent Epend... Recurrent Ewing... Recurrent Gliom... Recurrent Hepat... Recurrent Lange... Recurrent Malig... Recurrent Malig... Recurrent Medul... Recurrent Neuro... Recurrent Non-H... Recurrent Osteo... Recurrent Perip... Recurrent Prima... Recurrent Rhabd... Recurrent Soft ... Refractory Ewin... Refractory Glio... Refractory Hepa... Refractory Lang... Refractory Mali... Refractory Mali... Refractory Medu... Refractory Neur... Refractory Non-... Refractory Oste... Refractory Peri... Refractory Prim... Refractory Rhab... Refractory Rhab... Rhabdoid Tumor Stage III Osteo... Stage III Soft ... Stage IV Osteos... Stage IV Soft T... Stage IVA Osteo... Stage IVB Osteo... Wilms Tumor | Biopsy Biospecimen Col... Bone Marrow Asp... Bone Scan Computed Tomogr... Ensartinib Erdafitinib Laboratory Biom... Larotrectinib S... Magnetic Resona... Mutation Carrie... Olaparib Palbociclib Pharmacological... Positron Emissi... Radionuclide Im... Samotolisib Selpercatinib Selumetinib Sul... Tazemetostat Tipifarnib Ulixertinib Vemurafenib X-Ray Imaging | 12 Months - 21 Years | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
